Avenue Therapeutics is a pharmaceutical company that develop and commercialize its product principally for use in the acute/intensive care hospital setting. Co.'s product candidate is intravenous Tramadol, for the treatment of moderate to moderately severe post-operative pain. Co.'s product candidate, Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. The ATXI stock yearly return is shown above.
The yearly return on the ATXI stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ATXI annual return calculation with any dividends reinvested as applicable (on ex-dates).
|